Last update:

Clinical pharmacology news

HIV can develop resistance to blockbuster antiviral lenacapavir—but at a cost to the virus

Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the use of lenacapavir expands, scientists are probing a critical question: If the virus evolves resistance, ...

Developing a human hepatocyte model with enhanced drug-metabolizing enzyme activity

A research team led by Associate Professor Shinpei Yamaguchi and the late Professor Masako Tada of the Faculty of Science, together with Professor Yojiro Anzai and Lecturer Yohei Iizaka of the Faculty of Pharmaceutical Sciences ...

Understanding GLP-1 signaling: A path to better therapies

About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, obesity, or other conditions, according to a KFF Health Tracking poll. But many suffer from significant ...

FDA approves Dupixent for allergic fungal rhinosinusitis

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.